Skip to main content
L

Not yet reviewed: this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

5-MeO-MaLT

5-MeO-MaLT molecule structure5-MeO-MaLT molecule structure
This article is a stubmissing:
Subjective Effects
Interactions
Tolerance
Legality
Chemical Class
Tryptamine

5-MeO-MaLT is a psychedelic tryptamine related to 5-MeO-DALT. It was first described in the literature in 2004 and encountered as a novel designer drug in 2014. The substance remains uncommon, and its effects are likely similar to those of other psychedelic tryptamines, although little is known about it. Its pharmacology was investigated in a 2024 study comparing in vitro receptor profiles and acute in vivo effects of 5-MeO-DMT analogs.1

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~5 mg
Light5-10 mg
Moderate10-20 mg
Strong20+ mg

Subjective Effects

Subjective Effects not written up yet

Pharmacology

Pharmacodynamics

In functional studies, 5-MeO-MaLT reached up to 92% of serotonin's maximal effect at the 5-HT2A receptor, with an EC50 of 575 nM2, with activity supported by induction of the head-twitch response in rodents3. It also binds the serotonin 5-HT1A receptor with high affinity2.

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Toxicity

Lethal Dosage

Dose information is tentative and needs further research; no toxic or lethal dose is provided.

thermoregulatory/autonomic

Sweating and chills are listed among negative effects.

musculoskeletal

Muscle tension is listed among negative effects.

central nervous system

Confusion and insomnia are listed among negative effects.

History & Culture

5-MeO-MALT was first described in the literature in 2004 and was encountered as a novel designer drug in 2014. It was not included or mentioned in Alexander Shulgin's book *TiHKAL (Tryptamines I Have Known and Loved)*.

Legality

Legality not written up yet

References

Citations

  1. Serotonin 1A Receptors Modulate Serotonin 2A Receptor-Mediated Behavioral Effects of 5-Methoxy-N,N-dimethyltryptamine Analogs in Mice. ACS Chemical Neuroscience / PubMed (2024). https://doi.org/10.1021/acschemneuro.4c005131
  2. 5-MeO-MALT. Åklagarmyndigheten (Swedish Prosecution Authority) (2019). https://www.aklagare.se/globalassets/dokument/narkotikapreparat/0-9/5-meo-malt.pdf1234
  3. Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties. Molecular Psychiatry (2024). https://doi.org/10.1038/s41380-024-02506-81

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed: this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 5-MeO-MaLT article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.